GSK falls as Trump administration weighs future of CDC's HIV prevention division

British drugmaker GSK GSK.L falls as much as 2.6% to 1,492p as the U.S. health department is reviewing CDC's HIV prevention division for potential overlap

GSK's ViiV Healthcare unit focuses on HIV treatment and prevention

HHS says HIV prevention division could be dismantled

Carl Schmid, the executive director of the HIV+Hepatitis Policy Institute in Washington, says he understood all of the division's funding is "up in the air"

Schmid says a decision would be made this week on the funding, citing a government agency source

In 2024, sales from its HIV drugs grew 13%, contributing to about ~22.6% of GSK's total sales

GSK up ~14% YTD